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Introduction
Upon vascular injury, tissue factor (TF) binds plasma factor (F) VII(a). The FVIIa/TF complex catalytically activates FIX and FX, leading to the generation of thrombin and a fibrin clot. Beyond coagulation, FVIIa/ TF triggers cell-signaling events through protease-activated receptors (PARs) [1, 2] , which impact the pathophysiology of numerous diseases [3] [4] [5] [6] [7] [8] [9] . Tissue factor pathway inhibitor (TFPI) is the major endogenous regulator of FVIIa/TF activity. Through alternative RNA splicing, TFPIa and TFPIb isoforms are expressed in man and mouse [10] [11] [12] [13] . Transcripts for a third form, TFPIc, have been described in the mouse [14] . All TFPI isoforms contain the same N-terminus followed by two Kunitz-type protease inhibitor domains (K1K2); TFPIa contains a K3 domain and basic C-terminal region [10] ; TFPIb contains a sequence that directs the attachment of a glycosyl phosphatidyl inositol (GPI) membrane anchor [11, 15] and mouse TFPIc contains a short, unique C-terminal region [14] .
Human TFPI (hTFPI) limits FVIIa/TF activity through formation of a FVIIa/TF/FXa/TFPI quaternary complex [16] [17] [18] [19] [20] where K1 binds and inhibits FVIIa and K2 binds FXa; the K3 of hTFPIa lacks protease inhibitory activity [21] . hTFPI K2 also directly inhibits FXa [22] in a process that also involves an epitope within the K1 domain [23] [24] [25] [26] [27] and that for hTFPIa is dramatically enhanced by protein S (PS) (binding to K3) at phospholipid surfaces [28, 29] . hTFPIb, situated at the phospholipid surface of cells, inhibits FVIIa/TF and FXa well in the absence of PS [30, 31] .
Mouse models can provide insight into human physiology and disease, including abnormalities concerning hemostasis and thrombosis. In the case of TFPI, these studies have largely focused on sites of TFPI expression (e.g. endothelium and hematopoietic cells) using mouse strains with TFPIK1(À) disrupted genes [32] [33] [34] [35] [36] [37] [38] . Knowledge is lacking with respect to the roles each TFPI isoform plays in vivo and potential differences between the TFPI physiology in mice and man. Here we report studies using TFPI isoform-specific deleted mice that elucidate similarities and important distinctions between the physiology of TFPI in humans and mice.
Methods

Mice
The Washington University Animal Studies Committee approved all mouse studies. Control and CRISPR/Cas9-derived mouse lines were in a C57Bl/6N (B6; Taconic Biosciences, Rensselaer, NY, USA) genetic background and FVIIIKO (B6;129S-F8 tm1Kaz /J, Jackson Laboratories, Bar Harbor, ME, USA) mice in a C57Bl/6J-129S4/SvJae genetic background. Littermate TFPI(+/+)/FVIIIKO and TFPIa(À/À)/FVIIIKO mice were generated by mating TFPIa(+/À)/FVIIIKO animals.
Anti-mTFPI160 polyclonal IgG
Recombinant mouse TFPI (rmTFPI)160 (mature amino acids 1-160) was expressed and isolated using the pMAL system (New England Biolabs, Ipswich, MA, USA) and used to raise rabbit anti-mTFPI160 polyclonal IgG that was purified by protein A affinity (Captiva-PriMAB; Repligen, Waltham, MA, USA) chromatography. Control, pre-immune rabbit IgG was isolated in the same manner.
mTFPI ELISAs
Two assays, which used the same mTFPI standard (R&D Systems, Minneapolis, MN, USA) and produced consistent results, were used: the mTFPI DuoSet ELISA (R&D Systems) and an assay that uses anti-mTFPI160 IgG for capture and anti-mTFPI160 IgG-horseradish peroxidase (HRP) conjugated (Lighting Link; Innova Biosciences, Expedeon, San Diego, CA, USA) for detection.
Expression of recombinant (r) proteins
Mouse cDNAs were from Origene Technologies, Austin, TX, USA; mutants were produced by PCR-directed mutagenesis. A pcDNA3.4 vector was used to express wild-type (WT) rmTFPI (mature amino acids 1-157) and rmTFPIs K1(K32I) and K2(R103L) containing mutations at their critical P 1 residues, rmTF, rmFX and rmFVII using the Expi293 system (ThermoFisher, Waltham, MA, USA). rmTFPI levels were quantified by ELISA. Cells expressing rmTF were lysed by a freeze-thaw cycle in phosphate buffered saline (PBS) + 5 mM EDTA; membranes were isolated by centrifugation (10 000 g, 10 min), suspended in PBS and stored frozen. rmTF, rmFVII and rmFX were measured in clotting assays using human normal or factor-deficient plasmas (George King Biomedical, Overland Park, KS, USA). rmFXa was generated by a 30-min incubation of rmFX with 1% (w/w) FX-coagulant protein (XCP; Enzyme Research Laboratories, South Bend, IN, USA).
Mouse FXa and FVIIa/TF inhibition assays
Reactions were conducted using proteins in serum-free media. For mFXa assays, rmFXa (1.4 nM final) was preincubated with rmTFPIs (0-20 nM final) in 180 lL HSA (100 mM NaCl, 2 mg mL À1 bovine serum albumin, 20 mM Hepes, pH 7.2) for 20 min followed by the addition of 20 lL of 2 mM CS1165 substrate (Biophen). For mFVIIa/TF assays, excess mTF, mFVII (50 pM final) and mTFPIs (0-2 nM final) in 160 lL HSA + 5 mM CaCl 2 were mixed followed by the addition of 40 lL of mFX (1.4 nM in final volume) with 1 mM CS1165.
Mouse thrombin generation assay
Pooled, citrated C57Bl/6 mouse plasma was from Innovative Research, Novi, MI, USA. Individual mouse plasmas were prepared by centrifugation (5000 g 9 15 min) of blood drawn from the inferior vena cava into 1/9 volume of 3.8% sodium citrate. Corn trypsin inhibitor (CTI; Enzyme Research Laboratories) was added to 12.5 lg mL À1 . Plasma (20 lL) was incubated for 30 min with 40 lL HSA containing 50 lg mL À1 CTI without or with these other reagents: rmTFPIa (R&D Systems), antihuman protein S (anti-hPS; #A0384; Dako, Agilent Technologies, Santa Clara, CA, USA) and anti-mTFPI160. Next, 20 lL of 60 lg mL À1 rabbit brain cephalin (Pentapharm, Aesch, Switzerland) containing the specified concentration of mTF [from a mouse brain saline extract; mTF assayed by ELISA (Abcam, Cambridge, UK)] was added. Reactions were initiated by adding 20 lL of 1 mM Z-GGR-AMC (Sigma-Aldrich, Saint Louis, MO, USA) in 50 mM CaCl 2 . Data were collected using a Fluoroskan Ascent (ThermoFisher) instrument and analyzed as previously described [39] . Note that the anti-hPS antibody used in these studies reportedly cross-reacts with mouse PS (mPS), but the potency of its inhibition of mPS has not been established [40, 41] , and the rmTFPIa(1-259) reagent lacks the distal C-terminus domain, which is required for optimal FXa inhibition in the human system [29, 42] . Bovine FXa ligand and western blotting were performed as described [15] .
Mouse platelet isolation
Blood obtained with heparinized capillary tubes from the retro-orbital plexus of five to 10 mice was pooled, mixed gently with 3 volumes BSGCe (116 mM NaCl, 8.6 mM Na 2 HPO 4 , 1.6 mM KH 2 PO 4 , 13.6 mM sodium citrate, 11.1 mM glucose, 0.9 mM Na 2 EDTA, pH 6.8) ). A portion (2.5 mL) of the mixture was centrifuged in an SW55Ti rotor at 50 000 rpm (170 000 9 g) for 48 h at 4°C. Samples (0.5 mL) from the top and the bottom of the tube were dialyzed against 0.1 M NaCl, 0.02 M Hepes, 5 mM EDTA, and their mTFPI concentrations determined by ELISA.
Identification of TFPIc exon orthologs
Using EMBL-EBI ClustalW2, the mouse TFPIc exon sequence was aligned with the human, rat, rabbit, cat and dog TFPI genes to identify orthologs; the rat c exon encoding sequence was used to identify squirrel and Chinese hamster orthologs, and the human c exon homolog DNA sequence was used to identify other primate orthologs. National center for biotechnology information (NCBI) TFPI gene RNA-seq intron features were used to identify TFPIc exon splicing. followed by PCR amplification using a K2 domain encoding forward primer and a c exon reverse primer (see Table 1 ). Products were analyzed by agarose gel electrophoresis and sequenced.
Purification of mouse TFPI from plasma
Total plasma TFPI was isolated from 100 mL of citrated C57Bl/6 mouse plasma with 10 mL protease inhibitor cocktail (#2714; Sigma-Aldrich). Plasma was rocked overnight at 4°C with 4 mL of Affigel-10-linked (BioRad, Hercules, CA, USA) rabbit anti-mTFPI160 IgG (5 mg IgG per mL Affigel-10). The plasma/Affigel slurry was poured into a column and washed with 30 volumes of 0.5 M NaCl in TSE (5 mM EDTA, 20 mM Tris, pH 7.4).
Bound mTFPI was eluted with 0.02 M glycine, pH 2.5, adjusted to pH 7.4 with Tris (1.0 M, pH 8.3), and dialyzed into 0.15 M NaCl in TSE.
To isolate mouse lipoprotein-associated TFPI, three batches of 30 mL of citrated C57Bl/6 mouse plasma with 3 mL protease inhibitor cocktail were passed over a 3 9 180 cm Sephacryl 300 column (GE Healthcare, Chicago, IL, USA), equilibrated and eluted with 0.5 M NaCl in TSE. Fractions containing the major TFPI peak were pooled and further purified using the anti-mTFPI160 IgG Affigel-10 column procedure described above.
Purification of human TFPI from plasma
Total plasma TFPI was isolated from 100 mL of human plasma (Red Cross, Saint Louis, MO, USA) with 10 mL protease inhibitor cocktail. The plasma was filtered (0.45 lm) and then rocked overnight at 4°C with 4 mL of Affigel-10-linked anti-hTFPI 2H8 Mab (5 mg IgG per mL Affigel-10). The plasma/Affigel slurry was poured into a column and the hTFPI isolated using a similar procedure to that described above for the anti-mTFPI160 IgG Affigel-10 column.
Tandem mass spectroscopy (MS/MS) analysis
Tissue factor pathway inhibitor samples were digested with Lys-C, Lys-C and trypsin or Glu-C by conventional methods and analyzed using Mascot version 2.3.02 (Matrix Science, Boston, MA, USA). Scaffold version 4.0.5 (Proteome Software Inc., Portland, OR, USA) was used to validate MS/MS-based peptide and protein identifications. Peptides (≥5 residues) were established at greater than 90% probability (Protein Prophet TM algorithm).
Detection of phosphatidylinositol-specific phospholipase C (PIPLC) releasable mTFPI from mouse organs Membranes were prepared as previously described [15] from organs harvested from mice that had been perfused with 20 mL of PBS containing 5 mM EDTA and 5 U mL
Schaumburg, IL, USA). Membrane protein content was determined by the Bradford method. Membranes were treated without or with PIPLC (30 U mL À1 final) in HS containing 10% protease inhibitor cocktail for 1 h, followed by a 10-min centrifugation at 13 000 g. ELISA was used to measure mTFPI in the supernatants.
Generation of exon-specific knockout mice CRISPR/Cas9 technology [43] was used to create TFPI exon-specific deletions or c intron/exon splice site destruction. Sequences flanking the isoform-specific exon deletions and c spliced site disruption are shown in Table 2 .
Genotyping of mice was performed using the PCR Blood Phusion mix (#547L Thermo-Fisher). Reaction conditions were 98°C for 2 min 9 1 cycle; 98°C for 15 sec, 68°C for 30 sec, 72°C for 30 sec 9 30 cycles; and 72°C for 2 min 9 1 cycle. PCR products were analyzed by agarose gel electrophoresis. Primers (Integrated DNA Technologies, Coralville, IA, USA) used to identify wild-type and exon deletions are summarized in Table 1 .
Quantitative PCR of mTFPI isoform transcripts RNA was isolated from mouse organs as previously described [44] . Samples were analyzed by one-step RT-PCR using the Path-ID RT-PCR kit #4388639 (Ambion, Foster City, CA, USA) and standard conditions with an annealing temperature of 65°C. Individual reactions were run for each isoform using the fluorescein amidite (FAM) probe and primers listed in Table 1 and with the b-actin control (#4352933E; Applied Biosystems, Foster City, CA, USA) using the Applied Biosystems StepOnePlus Real-Time PCR system. Data were analyzed by the Livak method [45] .
Results
Structure/function analysis of mTFPI
To determine if the Kunitz domains in mouse and human TFPI function similarly, the abilities of WT truncated rmTFPI(1-157) and forms containing mutated K1 or K2 P 1 residues to bind to and inhibit mFXa and to inhibit mFVIIa/mTF activity in the presence of mFX(a) were assessed. WT and K1-mutated rmTFPI inhibited rmFXa similarly and bound HRP-labeled bovine FXa on a ligand blot (Fig. 1A,B,G) . Mouse K2-mutated rmTFPI did not inhibit rmFXa activity and did not recognize bovine FXa on ligand blot (Fig. 1C,G) . WT rmTFPI inhibited mouse rmFVIIa/rmTF activity (Fig. 1D) , but the K1-mutated and K2-mutated rmTFPIs each failed to significantly inhibit rmFVIIa/rmTF activity (Fig. 1E,F) . These results indicate that, as in man, the second Kunitz domain in mTFPI is responsible for the binding to and inhibition of FXa and that, in a FXa-dependent manner, the first Kunitz domain of mTFPI is responsible for inhibition of FVIIa/TF. An effect of anti-hPS antibodies in TFinduced thrombin generation assays could only be detected following the addition of rmTFPIa (Fig. 1H ).
These
Characterization of mouse plasma TFPI
The major form of mouse plasma TFPI migrates on SDS-PAGE as a~41 kDa protein, but elutes from sizeexclusion column chromatography at an apparent molecular weight of~270 kDa ( Fig. 2A) , suggesting that, like hTFPI, it may be bound to lipoprotein (high-density lipoprotein [HDL] is the predominant lipoprotein in the mouse plasma). Consistent with this notion, >98% of the TFPI in mouse plasma binds to fumed silica (Cab-O-Sil), which binds lipoproteins avidly [46] . greater than the concentration of TFPI in the bottom 20% of the sample. The major form of mTFPI in plasma was isolated by size exclusion chromatography followed by anti-mTFPI immunoaffinity chromatography. MS/MS analysis of this 'lipoprotein-associated' mTFPI identified it as a twoKunitz-domain (K1K2) form lacking detectible C-terminal isoform-specific sequences (Fig. 2B) . This result is similar to lipoprotein-associated hTFPI, which also appears to be a C-terminal truncated, two-Kunitz-domain (K1K2) form [48] . MS/MS analysis of total TFPI isolated from mouse plasma detected both mTFPIa-specific and mTFPIc-specific peptides, but no TFPIb-specific peptides (Fig. 2B) . MS/MS analysis of total hTFPI from human plasma demonstrated TFPIa-and TFPIb-specific peptides (Fig. 2C) .
TFPIc exon orthologs
The TFPIc-exon DNA sequence was reported to be unique to the mouse [14] . Selectively searching the TFPI genes revealed that sequences homologous with the mouse c exon are indeed present within the TFPI gene of many species, including man (Table 3) . NCBI databases contain no human transcripts with this sequence. Using appropriate primers and RT-PCR, messages from numerous human tissues were found to contain this TFPIc homologous sequence but in every case it was part of a TFPIb 3 0 -untranslated message, never an exon (data not shown). Of note, the 3 0 splice acceptor sequence for the TFPIc exon in mouse, rat, Chinese hamster, squirrel and rabbit is CAG, which is commonly used for splicing (71%); the corresponding splice sequence in man and other primates, GAG, is rarely utilized (<1%) for splicing (Table 3 ) [49] . NCBI TFPI gene RNA-seq intron features identified TFPIc exon splicing in mouse, rat and hamster, but not in rabbit, cat, dog or primates (data were insufficient to evaluate squirrel).
Mouse TFPI isoform transcripts
Tissue factor pathway inhibitor a exon-deleted, b exondeleted, b/c exons-deleted and c exon-disrupted mouse strains were generated using CRISPR/Cas9 technology. Amino acids in black correspond to peptide spectra identified in the mouse lipoprotein-associated TFPI sample; amino acids in light gray correspond to additional peptide spectra identified in the total mouse plasma TFPI sample; and amino acids in white correspond to regions where no corresponding peptide spectra were identified in either sample. (C) MS/MS analysis of human TFPI. Amino acids in gray correspond to peptide spectra identified in the total human plasma TFPI sample; and amino acids in white correspond to regions where no corresponding peptide spectra were identified. TFPI, tissue factor pathway inhibitor; mTFPI, mouse TFPI; MS/MS, tandem mass spectrometry.
The knockout (KO) mice, born at or near Mendelian ratios (Table 4) , appear healthy and reproduce. Tissue factor pathway inhibitor isoform transcript selective amplification was achieved by using a common upstream primer and isoform-specific primers that span their respective exon/exon splice sites (Fig. 3A-C) . Among six organs analyzed, the relative level of the c message ranged from 40% to 65%, the a message ranged from 30% to 50% and the level of the b message was 10% of the total TFPI message (Fig. 3D-I ).
Mouse TFPI isoform proteins
Two distinct mouse TFPI ELISAs showed TFPI in mouse plasma circulates at~20 times the level in man and is not detectably affected by heparin treatment: 31.5 AE 3.7 nM before and 29.7 AE 4.1 nM (n = 10) 15 min after 2 units of heparin (IP). Plasma mTFPI levels in TFPIa(À/À) and TFPIb(À/À) mice are similar to those in WT mice (~100%). They are~50% in TFPIc(+/À) and TFPIb/c (+/À) mice and ≤2% in TFPIc(À/À) and TFPIb/c(À/À) mice (Fig. 4A) . Thus, the major form of mouse plasma TFPI is derived from mTFPIc, not a or b.
Studies of mice with combined TFPIb/c(À/À) gene deletion (expressing a only) show a plasma level of TFPIa of 66.8 AE 12.9 pM that increases 7.3 AE 2.5-fold after heparin treatment (Fig. 4B) . These baseline TFPIa measurements represent a total value and the distribution of TFPIaderived 'free' and lipoprotein-associated forms, if any, remains to be determined. Four individual experiments using platelets isolated from five to 10 mice, showed the level of TFPI in platelets (at 850 000/lL) in wild-type mouse blood was 74.6 AE 16.0 pM. Platelet TFPI is absent in TFPIa KO mice, confirming a previous report [50] that in mice, like humans, platelet TFPI is TFPIa (Fig. 4C) .
Membranes isolated from tissues of WT, b KO, c KO and b/c KO mice were treated without or with PIPLC and the released TFPI measured by ELISA (Fig. 4D) . PIPLC treatment released TFPI from WT membranes, whereas membranes from TFPIb KO and TFPIb/c KO mice showed no significant release of TFPI with PIPLC treatment. These results are consistent with TFPIb being the predominant GPI-anchored isoform. Of interest, deletion of the c exon results in a significant~2.7-fold increase in PIPLC-releasable TFPIb. It is plausible that the loss of the c exon splicing increases RNA splicing to the nearby b exon, leading to increased b protein.
Because of its potent PS-and C-terminal-dependent inhibition of FXa, TFPIa plays the paramount anticoagulant role in in vitro assays of coagulation in human plasma. Compared with TFPIa, C-terminal truncated forms of recombinant hTFPI and lipoprotein-associated hTFPI containing only K1 and K2, like mouse lipoprotein-associated TFPI, are poor inhibitors of FXa [29, 42] and their anticoagulant effect is difficult to detect in plasma coagulation assays, including standard thrombin generation assays [51] [52] [53] . To demonstrate that the lipoprotein-associated, C-terminal truncated form of TFPI in mouse plasma possesses relevant anticoagulant activity, the in vitro thrombin generation assay was performed using plasma from mice with hemophilia (FVIIIKO), which reduces the dependence of the results on FXa inhibition. Under these conditions, thrombin generation in the plasma obtained from both TFPIa(+/+)/ FVIIIKO and TFPIa(À/À)/FVIIIKO mice was dramatically enhanced by anti-mTFPI160 antibodies (Fig. 4E,F) .
Discussion
Mouse models have been used extensively to evaluate the role of TFPI in hemostasis and thrombosis. Although mice possess TFPIc transcripts [14] that are not present in humans, potential differences between TFPI physiology in humans and mice have not been carefully assessed. Such studies have been hampered by the lack of isoformspecific antibodies for each mouse TFPI isoform. Here, a variety of methods, including MS/MS analysis and CRISPR/Cas9 technology, to generate mice with specific TFPI isoform deletions have been used to better compare human and mouse TFPI physiology. A major result of the current work is the demonstration that mouse plasma TFPI, which circulates at a level 20-fold the level of TFPI in human plasma, is derived predominantly from mTFPIc, rather than another mTFPI isoform (e.g. mTFPIb) [54, 55] . Although the mouse TFPIc exon homologous sequence was reportedly not present in other species [14] , we found TFPIc orthologs in several species, including man. RNA-seq data indicate the c exon is used in mouse, rat and hamsters, but the TFPIc ortholog sequence in man is not recognized as an exon, perhaps in part because of an unfavorable 3 0 acceptor splice site sequence.
Matching the hTFPI Kunitz-domain functions [21] , we found that the mTFPI first and second Kunitz domains inhibit FVIIa and FXa, respectively, and that the FVIIa/ TF inhibition is dependent on FXa.
In human plasma, the major form of TFPI appears to be C-terminal truncated, two-Kunitz-domain (K1K2) hTFPI that is associated with lipoproteins (low-density lipoprotein [LDL] > HDL) [48] . Whether the TFPI isoform source for lipoprotein-associated human TFPI is hTFPIa, hTFPIb or both has not been determined. The major form of TFPI circulating at high levels bound to lipoprotein in mouse plasma also appears to be a truncated K1K2 mTFPI form and is derived predominantly from mTFPIc. The mechanism responsible for the association of hTFPI and mTFPI with plasma lipoproteins is not known.
Human TFPIa circulates in plasma at low levels, which are comparable to the levels of TFPIa carried by platelets in human blood (at~200 000 platelets/lL) [56] . Heparin administration in man increases total hTFPI in plasma 2-to 3-fold as a result of a~15-fold increase in hTFPIa, presumably released by endothelial cells [57] [58] [59] . It has been reported that mouse TFPIa differs from its human counterpart in that it is not produced by endothelial cells and is not present in plasma [60] . Our MS/MS results, however, demonstrate the presence of TFPIa in mouse plasma and, based at least on the results in mice with combined TFPIb/c(À/À) gene deletion (expressing a only), mTFPIa circulates in mouse plasma at low levels, which, like in humans, are comparable to the levels of TFPIa in the platelets in mouse blood (at~850 000/lL). In contrast to the case in humans, we find that an effect of heparin-induced release of mTFPIa on total mouse plasma TFPI levels is difficult to detect because of the high plasma levels of TFPI derived from TFPIc. This result differs from a previous report that used a different assay method [54] . In the TFPIb/c-deleted mice expressing only mTFPIa, however, a several-fold increase in TFPIa can be demonstrated following heparin treatment.
PIPLC treatment, which cleaves GPI-anchored proteins, releases TFPI from cell membranes [61] . For some time it was thought that this represented TFPIa bound to an unidentified GPI-anchored co-receptor [62, 63] . It has since been shown for human placenta and endothelial p r e -h e p a r i n p o s t -h e p a r i n cells that TFPIb is the form released from the cell surface by PIPLC [15] . Consistent with the latter finding, PIPLC treatment of membranes from TFPIb KO and TFPIb/c KO mice show no significant release of TFPI, in contrast to controls. Thus, mTFPIb also appears to be the predominant GPI-anchored TFPI isoform in the mouse. MS/MS analysis demonstrated the presence of peptides from hTFPIa and hTFPIb in human plasma and from mTFPIa and mTFPIc in mouse plasma. Our inability to detect mTFPIb peptides in mouse plasma, however, must be considered cautiously. The amino acid sequence of mTFPIb is such that its processing to contain a GPI anchor and potential proteolytic shedding from a membrane surface would produce mTFPIb peptides that would not have been identified under the conditions of our MS/MS analysis.
The availability of TFPIa and combined TFPIbc KO mice enabled us to validate RT-PCR assays with respect to TFPI isoform specificity. For example, assays for isoform-specific transcripts show no signals in their respective isoform-deleted mice. With these assays, the levels of TFPIa and TFPIc transcripts in wild-type mice are roughly similar across tissues (~40-60% each) and the TFPIb message represents~10% of the total TFPI transcripts. It has been reported that mouse tissues express 5-50 times more TFPIa than TFPIb and that the TFPIc message is expressed at~2-fold the level of TFPIb [54] . The discrepancy between studies may be a result of the use of different primers, reagents and assay conditions.
The anticoagulant activity of two-Kunitz-domain (K1K2) forms of TFPI is difficult to detect in in vitro plasma coagulation assays because, compared with TFPIa, they are poor inhibitors of FXa. The K1K2 forms of TFPI, however, are not inert (Fig. 4E ) and possess potent anti-FVIIa/TF activity (Fig. 1D) . Moreover, they probably function in vivo because they inhibit FVIIa/TF at cultured cell surfaces and under conditions mimicking vascular flow in a fashion comparable to full-length TFPIa [64] [65] [66] .
In sum, the properties of TFPIa and TFPIb in the mouse appear to mirror those of the same isoforms in humans. Mice differ dramatically from man, however, in that their plasma contains a 20-fold higher level of K1K2, a C-terminal truncated TFPI derived from TFPIc, an isoform not found in man. In vitro coagulation assays are an incomplete measure of the overall and isoform-specific pathophysiologic roles of TFPI as they do not detect the potential in vivo contributions of vascular flow and endogenous cell-surface-associated TFPIb, nor do they assess potential functional properties of TFPI unrelated to thrombin generation. Here, in vivo experimentation is required and TFPIc gene-deleted mice, expressing only the TFPIa and TFPIb isoforms, may serve as a more appropriate human surrogate. Moreover, their comparison with mice expressing only mTFPIa and only mTFPIb in mouse models of hemostasis, thrombosis, inflammation, cancer/ metastasis, etc., could provide insight into the potential differential roles of the TFPI isoforms in these human diseases. 
